Atlantic Labs is an early-stage venture capital investment firm that is based in Berlin, Germany. They seek to back mission driven founders as early as possible, and help them build world leading companies. They are currently active in areas including Digital Health, Future of Work, AI/Machine Learning, Mobility, Industrial Automation, Fintech, Proptech, and Community.

Atlantic Labs

Investment firm which in backing biotech, offering investors the opportunity to back promising medical innovations via the EIS and  SEIS.

O2h Ventures

We invest in early stage technology businesses and, in exceptional cases, will create them from scratch with outstanding partners. We pride ourselves on being open minded and ready to support ideas orthogonal to consensus views.

Delin Ventures

Accel is an early and growth-stage venture capital firm that powers a global community of entrepreneurs. Accel backs entrepreneurs who have what it takes to build a business.  Accel’s vision for entrepreneurship and business enables it to identify and invest in the companies that will be responsible for the growth of next-generation industries. Accel-backed companies include Atlassian, Braintree, Cloudera, DJI, Dropbox, Dropcam, Etsy, Facebook, Flipkart, Lookout Security, MoPub, Qualtrics, Slack, Spotify, Supercell, Vox Media, and others.

Accel

Boston Millennia Partners (BMP) has a long and successful history of growth capital investing on a national scope. Our Core Company Investment Strategy, combined with our international network of relationships and deep industry expertise, sets us apart from other investor groups and enables us to contribute meaningfully to our portfolio companies. The company focuses on investment opportunities within the healthcare and business services industries. Outsourcing and software as a service business companies are of particular interest for investment. Boston Millennia Partners' goal is to be supportive and effective investing partners, and establish productive relationships with its business partners that create long-term value. The company seeks to partner with entrepreneurs who share our goal of building enduring, large-scale businesses that result in personal fulfillment and superior financial returns.  Over the past thirty years, it has implemented an investment approach that centers on active participation with our portfolio companies.  Its goal is to be supportive and effective investing partners and establish productive relationships with its business partners that create long-term value.

Boston Millennia Partners

XTX Ventures is the venture capital arm of XTX Markets. XTX Markets is a leading, innovation-driven algorithmic trading firm. XTX Ventures focuses on early stage startups (Seed to Series A) applying machine learning and leverages XTX Markets’ deep expertise in ML and financial technology to help grow and enhance those businesses. We are geography and industry agnostic.

XTX Ventures

Day One Capital is an early-stage venture capital fund that works with entrepreneurs and technology start-ups from Europe. As an early-stage technology investor, managing privately financed funds, Day One Capital seeks to find and join the most exciting Central Eastern European teams on their global mission.

Day One Capital

Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.  This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.  Merck GHI has $500M under management and provides growth capital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.  With a vision that data will be the currency in healthcare, GHI invests broadly in digital health.  GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation.   Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.

Merck Global Health Innovation Fund

Mercia Fund Managers is a venture capital fund manager with two funds totalling £12.8 million under management. Mercia Fund Managers focuses its efforts on the West Midlands region and benefits from a mixture of public- and private-sector fund investors. Mercia Fund Managers provides venture capital for early-stage technology start-ups that are located in the West Midlands. Potential investees must demonstrate their potential for rapid growth and will possess a strong proprietary position with respect to their technology, intellectual property, and products. Mercia Fund Managers is based in central Birmingham and is regulated by the Financial Services Authority. The company is also a member of the British Private Equity and Venture Capital Association. Mercia Fund Managers will typically make an initial investment offer of between £50,000 and £250,000 of venture capital, but has the capacity to follow its money at subsequent investment rounds, up to an overall limit of £1 million of venture capital per company. Later rounds of financing will usually involve syndication with other venture capital investors, often from outside of the West Midlands.

Mercia Fund Managers

MMV is a multi-stage, global venture capital firm investing in enterprise software, cybersecurity, financial technology, and digital health companies. We help accelerate the growth of the companies we partner with by providing capital, connections and advice. MMV’s sole limited partner is MassMutual, a Fortune 500 financial services company with assets under management of $616 billion (Dec 2020).

MassMutual Ventures

Turbine

Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer.

<div>Turbine operates Simulated Cell, a proprietary simulation-based drug discovery platform that generates novel oncology therapies. The platform models human cell behavior to run a vast number of cloud-based experiments. Turbine&rsquo;s simulations also measure the changes in tumor cells across the entire R&amp;D process. The company can reportedly design and develop drugs for 70% of cancers.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Turbine operates Simulated Cell, a proprietary simulation-based drug discovery platform that generates novel oncology therapies. The platform models human cell behavior to run a vast number of cloud-based experiments. Turbine&rsquo;s simulations also measure the changes in tumor cells across the entire R&amp;D process. The company can reportedly design and develop drugs for 70% of cancers.
 
 
 As of March 2024, the company&rsquo;s internal pipeline included four drug candidates in early discovery stages. However, it has several partnership programs that are from preclinical to commercialization stages.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies that leverage its platform, including 1) Bayer to support its oncology pipeline (October 2016), 2) Cancer Research Horizons to identify target patient populations (
 <a href="https://turbine.ai/news/ai-powered-cancer-cell-simulations-will-be-used-to-identify-novel-disease-positioning-strategies-in-cancer-research-uks-latest-biotech-partnership/">
 January 2023
 </a>
 ), and 3) AstraZeneca to discover drug resistance in hematological cancers (
 <a href="https://sp-edge.com/updates/25239">
 January 2024
 </a>
 ).&nbsp;
 
 
 In February 2024, the company joined Ginkgo Bioworks&rsquo; Technology Network to create an ecosystem of technology partners for cell programming.
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/19579">
 June 2023
 </a>
 , the company raised EUR 5.5 million (USD 6 million) from MassMutual Ventures (MMV) in its extended Series A funding round, bringing the total Series A funds to EUR 25.5 million (USD 28 million). The funds were used to advance the company&rsquo;s internal pipeline and develop its AI-powered biology simulation platform.
 
</div>

<div>
 
 e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies.&nbsp;
 
 
 The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.
 
 
 Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/e-therapeutics-signs-research-collaboration-agreement-novo-nordisk/">
 Novo Nordisk
 </a>
 (December 2018), 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/collaboration-galapagos-discover-new-therapeutic-strategies-treatment-idiopathic-pulmonary-fibrosis-and-other-fibrotic-condition/">
 Galapagos
 </a>
 (June 2020), and 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/immuno-oncology-research-collaboration-iteos-therapeutics/">
 iTeos Therapeutics 
 </a>
 (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration.&nbsp;
 
 
 Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson&rsquo;s disease.&nbsp;
 
 
 Funding and financials
 
 
 In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange&rsquo;s public market for small and medium-sized growth companies, under the ticker symbol &ldquo;ETX&rdquo;. Further in 
 <a href="https://sp-edge.com/updates/13462">
 September 2022
 </a>
 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&amp;G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.
 
</div>

eTherapeutics

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

<div>
 
 Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris&rsquo;s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.
 
</div>

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

Turbine

AI Drug Discovery

Key stats

Recent Updates

Turbine partners with AstraZeneca to discover drug resistance in hematological cancers

Turbine raises additional EUR 5.5 million in Series A funding

Turbine raises EUR 20 million Series A

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless